Skip to main content
Journal cover image

6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias.

Publication ,  Journal Article
Armaganijan, LV; Staico, R; Moreira, DAR; Lopes, RD; Medeiros, PTJ; Habib, R; Melo Neto, J; Katz, M; Armaganijan, D; Sousa, AGMR; Mahfoud, F ...
Published in: JACC Cardiovasc Interv
June 2015

OBJECTIVES: This study aimed to assess 6-month outcomes in patients with implantable cardioverter-defibrillators (ICDs) undergoing renal sympathetic denervation (RSD) for refractory ventricular arrhythmias (VAs). BACKGROUND: ICDs are generally indicated for patients at high risk of malignant VAs. Sympathetic hyperactivity plays a critical role in the development, maintenance, and aggravation of VAs. METHODS: A total of 10 patients with refractory VA underwent RSD. Underlying conditions were Chagas disease (n = 6), nonischemic dilated cardiomyopathy (n = 2), and ischemic cardiomyopathy (n = 2). Information on the number of ventricular tachycardia (VT)/ventricular fibrillation (VF) episodes and device therapies (antitachycardia pacing/shocks) in the previous 6 months as well as 1 and 6 months post-treatment was obtained from ICD interrogation. RESULTS: The median number of VT/VF episodes/antitachycardia pacing/shocks 6 months before RSD was 28.5 (range 1 to 106)/20.5 (range 0 to 52)/8 (range 0 to 88), respectively, and was reduced to 1 (range 0 to 17)/0 (range 0 to 7)/0 (range 0 to 3) at 1 month and 0 (range 0 to 9)/0 (range 0 to 7)/0 (range 0 to 3) at 6 months afterward, respectively. There were no major procedure-related complications. Two patients experienced sustained VT within the first week; in both cases, no further episodes occurred during follow-up. Two patients were nonresponders: 1 with persistent idioventricular rhythm and 1 with multiple renal arteries and incomplete ablation. Three patients died during follow-up. None of the deaths was attributed to VA. CONCLUSIONS: In patients with ICDs and refractory VAs, RSD was associated with reduced arrhythmic burden with no procedure-related complications. Randomized controlled trials investigating RSD for treatment of refractory VAs in patients with increased sympathetic activity are needed.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JACC Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

June 2015

Volume

8

Issue

7

Start / End Page

984 / 990

Location

United States

Related Subject Headings

  • Ventricular Fibrillation
  • Treatment Outcome
  • Time Factors
  • Tachycardia, Ventricular
  • Sympathectomy
  • Risk Factors
  • Renal Artery
  • Prospective Studies
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armaganijan, L. V., Staico, R., Moreira, D. A. R., Lopes, R. D., Medeiros, P. T. J., Habib, R., … Abizaid, A. (2015). 6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias. JACC Cardiovasc Interv, 8(7), 984–990. https://doi.org/10.1016/j.jcin.2015.03.012
Armaganijan, Luciana V., Rodolfo Staico, Dalmo A. R. Moreira, Renato D. Lopes, Paulo T. J. Medeiros, Ricardo Habib, Jônatas Melo Neto, et al. “6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias.JACC Cardiovasc Interv 8, no. 7 (June 2015): 984–90. https://doi.org/10.1016/j.jcin.2015.03.012.
Armaganijan LV, Staico R, Moreira DAR, Lopes RD, Medeiros PTJ, Habib R, et al. 6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias. JACC Cardiovasc Interv. 2015 Jun;8(7):984–90.
Armaganijan, Luciana V., et al. “6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias.JACC Cardiovasc Interv, vol. 8, no. 7, June 2015, pp. 984–90. Pubmed, doi:10.1016/j.jcin.2015.03.012.
Armaganijan LV, Staico R, Moreira DAR, Lopes RD, Medeiros PTJ, Habib R, Melo Neto J, Katz M, Armaganijan D, Sousa AGMR, Mahfoud F, Abizaid A. 6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias. JACC Cardiovasc Interv. 2015 Jun;8(7):984–990.
Journal cover image

Published In

JACC Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

June 2015

Volume

8

Issue

7

Start / End Page

984 / 990

Location

United States

Related Subject Headings

  • Ventricular Fibrillation
  • Treatment Outcome
  • Time Factors
  • Tachycardia, Ventricular
  • Sympathectomy
  • Risk Factors
  • Renal Artery
  • Prospective Studies
  • Middle Aged
  • Male